All In Biotech

Drug Trial Radar · NCT04276233

Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma

A Phase 4, Open-label, Single Arm, 24-week, Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged ≥18 Years With Severe Eosinophilic asthMa (PRISM)

Last checked: Nov 20, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

Jun 29, 2021

Primary completion

Oct 28, 2023

Study completion Oct 28, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Tech Observer
First posted
Feb 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Mepolizumab is a humanized monoclonal antibody (IgG1, kappa) that blocks interleukin- 5 (IL-5) thus inhibits production and survival of eosinophils. The aim of this phase 4, open-label, single-arm study is to evaluate the safety and efficacy of Mepolizumab 100 mg SC administered every 4 weeks in Indian participants aged 18 years or above with severe eosinophilic asthma. After the first dose of mepolizumab, participants will receive 5 more doses of mepolizumab at 4 weekly intervals. Following the last dose of mepolizumab, the end of the study Visit will occur 4 weeks later. During the treatment period, OCS use and dose adjustment in participants will be as per the investigator's discretion and clinical practice.

Conditions

  • Asthma

Interventions

  • MepolizumabDrug

    Mepolizumab will be available as a lyophilized cake in sterile vials and will be reconstituted with sterile water for injection, just prior to use.

  • SalbutamolDrug

    Salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)Time frame: Up to Week 24
  2. Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Up to Week 24

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Ahmedabad, India

  • GSK Investigational Site

    Byculla Mumbai, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Jaipur, India

  • GSK Investigational Site

    Kanpur, India

  • GSK Investigational Site

    Kolkata, India

  • GSK Investigational Site

    Nagpur, India

  • GSK Investigational Site

    New Delhi, India

  • GSK Investigational Site

    Noida, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Pune, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.